Saturday 17 October 2026 Export ALVO’s income statement to Excel — free account

Alvotech

ALVO Healthcare Drug Manufacturers Specialty & Generic

Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,311.0%, EPS fell 99.5%, free cash flow fell 496.6% and total debt rose 16.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

5.00 0.31 −5.84%

Follow ALVO

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: 8.9×
Dividend yield: —
F-score: 3/9
Altman Z: −0.98
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 41.01%

Capital & Financial Ratios $m

Market Cap 2,070.00

Revenue 293.27

Net Income 70.68

Free Cash Flow (211.69)

Net Debt 1,163.26

Current Ratio 1.65

Debt/Equity (6.82)

P/E ratio 0.00

Fwd P/E 8.85

P/S ratio 5.02

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 80.57%

Next Y EPS Growth 1,271.79%

Next Y revenue growth 12.45%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.36%

10-year low 10-year high

EV/Sales against its own 10 years 11.69%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	51	172	143
Receivables	42	160	70	47
Inventory	74	128	220	227
Other	67	115	111	129
	195	455	574	545

	2023	2024	2025	Q'26
Payables	81	67	126	133
ST’ Debt	38	33	37	42
Other	132	84	128	142
	261	193	304	331

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	91.85%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	106	—	—	—	—
’25	133	—	—	—	586
’24	37	—	—	—	490
’23	16	4	18	—	91
’22	0	—	19	24	83

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(60)	(20)	—	—	—
’25	13	56	13	—	(50)
’24	(75)	(51)	(198)	—	(237)
’23	(86)	(38)	(245)	—	(312)
’22	(38)	(141)	(248)	(64)	(312)
’21	0	0	0	(228)	(228)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(107)	(65)	—	—	—
’25	(11)	27	(68)	—	(146)
’24	(80)	(58)	(224)	—	(294)
’23	(100)	(49)	(281)	—	(359)
’22	(51)	(168)	(286)	(64)	(361)
’21	0	0	0	(269)	(269)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.00	—	—	—	—
’25	0.35	—	—	—	0.10
’24	(0.89)	—	—	—	(0.87)
’23	(1.24)	0.72	(0.70)	—	(2.43)
’22	(0.43)	—	(0.03)	(1.29)	(2.60)
’21	1.13	(0.04)	0.18	(2.19)	(0.92)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	5.20	6.70	9.15	4.32	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	14.04	14.60	18.00	13.70
People
People	Employees	—	—	—	—	4	4	947	1,026	1,032	1,460
	Revenue/emp, $m	—	—	—	—	0.00	9.19	0.09	0.09	0.47	0.40
Income, $m
Income, $m	Revenue	—	—	—	—	—	37	83	91	490	586
	Gross margin, %	—	—	—	—	—	100.00	22.80	(75.93)	62.16	59.82
	EBT	—	—	—	—	(9)	(149)	(552)	(651)	(218)	136
	EBT margin, %	—	—	—	—	0.00	(405.74)	(664.40)	(712.04)	(44.43)	23.25
	Net income	—	0	—	—	(9)	(102)	(514)	(552)	(232)	28
	Depreciation	—	—	—	—	—	18	20	24	31	38
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.33	0.42	0.40	1.83	2.02
	Earnings	—	—	—	—	(1.53)	(0.92)	(2.60)	(2.43)	(0.87)	0.10
	Cash flow	—	—	—	—	(0.05)	(2.06)	(1.58)	(1.37)	(0.88)	(0.17)
	Capex	—	—	—	—	0.00	(0.37)	(0.25)	(0.20)	(0.21)	(0.33)
	Free cash flow	—	—	—	—	(0.05)	(2.43)	(1.83)	(1.58)	(1.10)	(0.50)
	Book value	—	—	—	—	(4.80)	(1.23)	(2.85)	(4.10)	(1.54)	(0.98)
	Shares, m	—	—	—	—	6	111	198	227	268	290
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	76.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	0.00	49.04	43.41	7.60
	P/B	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	EV/Sales	—	—	—	—	—	0.00	0.00	64.38	56.99	13.47
	EV/FCF	—	—	—	—	—	(6.47)	(5.23)	(7.48)	(6.65)	(9.40)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	(228)	(312)	(312)	(237)	(50)
	Capex	—	—	—	—	—	(41)	(49)	(46)	(57)	(96)
	Free cash flow	—	—	—	—	0	(269)	(361)	(359)	(294)	(146)
Balance, $m
Balance, $m	Working capital	—	—	—	—	1	8	63	(66)	262	270
	Total debt	—	—	—	—	0	401	765	960	1,069	1,299
	Net debt	—	—	—	—	(1)	383	698	949	1,017	1,127
	Shareholders’ equity	—	—	—	—	(29)	(136)	(564)	(932)	(413)	(284)
Returns, %
Returns, %	ROA	—	—	—	—	(7.37)	(23.90)	(72.01)	(62.04)	(21.36)	2.06
	ROIC	—	—	—	—	0.00	(59.40)	(161.92)	(1,343.43)	7.20	5.80
	ROE	—	—	—	—	(4.16)	123.27	146.73	73.72	34.47	(8.01)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%	Compare
Median of peers	$2.2B	14.9×	14.5×	+27.31%	+194.59%	+2.09%	61.63%	8.88%

All 86 Drug Manufacturers Specialty & Generic stocks →

Alvotech (ALVO) key facts

Strength: Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024.
Alvotech (ALVO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALVO traded at $5.00, a market capitalization of $2.1 billion.
Return on equity was −8.01% and debt-to-equity -6.82.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.98 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.